Sells single-use medical devices for vascular access, interventional procedures and surgery to hospitals and healthcare providers.
10-K for FY2025, filed Feb 27, 2026Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce…View ↗
Vascular and Emergency Medicine ("Vascular"): Our Vascular product portfolio comprises devices designed to support a variety of critical…View ↗
Interventional: Our Interventional product category offers devices that facilitate a variety of applications to diagnose and deliver…View ↗
Surgical: Our Surgical product category consists of single-use and reusable devices designed for a variety of surgical procedures. These…View ↗
Hospitals, healthcare providers and distributors pay for medical devices when they ship; payment is generally due 30 days after invoicing.
10-K for FY2025, filed Feb 27, 2026Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a…View ↗
10-K for FY2025, filed Feb 27, 2026
FY2025 revenue by product or service ↗$2B
10-K for FY2025, filed Feb 27, 2026
$2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Vascular Access
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
46%
FY2022: 24%
|
Vascular Access, FY2025
$917.7M Sources
|
Sold outright |
|
Interventional
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
33%
FY2022: 16%
|
Interventional, FY2025
$647.8M Sources
|
Sold outright |
|
Surgical
Sold outright
10-K for FY2025, filed Feb 27, 2026 |
21%
FY2022: 14%
|
Surgical, FY2025
$418.2M Sources
|
Sold outright |
|
Other
|
0.5%
FY2022: 10%
|
Other, FY2025
$9M Sources
|
Hospitals and healthcare providers buy through Teleflex's direct sales force or distributors; sales also go directly to distributors through its sales force, independent representatives and distributor networks.
10-K for FY2025, filed Feb 27, 2026
No. It lost $905.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 5, 2026
$927.4MView ↗
8-K, filed Aug 6, 2026
Reducing GAAP revenue growth guidance range to 13.40% to 14.40% Reducing GAAP EPS from continuing operations guidance range to $2.54 to…View ↗
8-K, filed Aug 3, 2026
On August 3, 2026 (the “Closing Date”), Teleflex Incorporated (the “Company”) completed the previously announced sale of its Original…View ↗
Shrinking. Revenue fell 29% in 4 years, from $2.8B in FY2021 to $2B in FY2025, about 8% a year.
Expanded interventional range
Teleflex added drug-coated balloons, stents and balloon catheters through its acquisition of BIOTRONIK's Vascular Intervention business, alongside its existing coronary and peripheral products.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 27, 2026Interventional: Our Interventional product category offers devices that facilitate a variety of applications to diagnose and deliver…View ↗
OEM business planned for sale
The older report described OEM as a reportable segment supplying devices to medical-device makers; the latest report includes OEM among the businesses Teleflex plans to sell.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 27, 2026
Loading...